Chicago, IL – May 30, 2026 – In a significant development for patients battling relapsed or refractory classical Hodgkin Lymphoma (cHL), AstraZeneca presented initial clinical data for its novel investigational therapy, AZD-3470, at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The Phase I PRIMAVERA study (NCT06137144) revealed encouraging safety and efficacy signals for AZD-3470, a first-in-class inhibitor of protein arginine methyltransferase 5 (PRMT5), in a heavily pretreated patient population. These findings mark a potential turning point for an indication that has seen limited therapeutic advancements in recent years.
The presentation, delivered on May 30th, provided a first look at the drug’s performance in a dose-escalation cohort of 39 adult patients diagnosed with relapsed/refractory cHL. This group had undergone extensive prior treatment, with a median of six lines of therapy, including established standards of care such as brentuximab vedotin and anti-PD-1 agents. AZD-3470 was administered as a monotherapy, with doses escalating from 25mg to 600mg, as researchers sought to determine the maximum tolerated dose (MTD) and evaluate preliminary anti-tumor activity.
The data showcased a generally acceptable safety profile, with most treatment-emergent adverse events (TEAEs) being mild to moderate in severity. Crucially, no dose-limiting toxicities (DLTs), treatment discontinuations due to TEAEs, or deaths attributed to the investigational drug were reported up to the highest dose tested. This suggests that AZD-3470 possesses a manageable safety margin, a critical factor for any new therapeutic agent, especially in a patient population already burdened by disease and prior treatments.
Unveiling the Mechanism: Targeting a Key Aberration in cHL
The scientific rationale behind AZD-3470’s development lies in its targeted approach to a molecular vulnerability prevalent in classical Hodgkin Lymphoma. PRMT5 is an enzyme that plays a crucial role in various cellular processes, including gene expression and DNA repair. In a significant majority of cHL patients, estimated to be over 80%, the gene responsible for producing methylthioadenosine phosphorylase (MTAP) is epigenetically silenced. This silencing leads to an upregulation of PRMT5 activity, creating a dependency on this enzyme for cancer cell survival and proliferation.
By inhibiting PRMT5, AZD-3470 aims to disrupt these aberrant cellular pathways, thereby inducing cancer cell death. This targeted mechanism offers a distinct advantage over traditional chemotherapy, which often exerts its effects non-selectively, leading to broader toxicity. The development of PRMT5 inhibitors represents a significant advancement in precision oncology, seeking to exploit specific molecular characteristics of cancer cells to achieve therapeutic benefit with potentially improved tolerability.
Early Efficacy Signals: A Glimmer of Hope for Heavily Pretreated Patients
While the initial data focused on safety, the efficacy signals observed in the PRIMAVERA trial were particularly encouraging, especially considering the challenging nature of relapsed/refractory cHL. Among patients treated with doses of 450mg or higher, a notable proportion demonstrated a clinical response. Specifically, in the cohort receiving 450mg of AZD-3470, an objective response rate (ORR) of 58% was reported, with 35% achieving a complete response (CR).
These response rates further improved in patients who received the highest tested dose of 600mg. In this subgroup of 16 patients, the ORR climbed to 63%, with an impressive 44% achieving a complete response. These figures, while derived from a small patient cohort, represent a significant clinical benefit for individuals with limited treatment options. The achievement of complete responses, where all detectable signs of cancer are eliminated, is a particularly noteworthy outcome and suggests the potential for durable disease control.
The median duration of exposure to AZD-3470 at the time of reporting was 15 weeks. A substantial 51% of patients were still receiving treatment at the time of the data cutoff, indicating that the therapy was well-tolerated for an extended period in a significant portion of the study participants. This ongoing treatment further underscores the acceptable safety profile and suggests that the drug may offer sustained therapeutic benefit.
Contextualizing the Data: Benchmarking Against Current Standards
To fully appreciate the significance of these early findings, it’s essential to place them in the context of existing treatment paradigms for heavily pretreated R/R cHL. Historically, this patient population has faced a challenging prognosis, with few salvage options offering substantial and durable responses. The emergence of anti-PD-1 agents, such as Merck & Co.’s Keytruda (pembrolizumab) and Bristol Myers Squibb’s Opdivo (nivolumab), represented a significant leap forward, offering response rates that had not been seen before in this setting.
For instance, data from pivotal trials like Keynote-087 for Keytruda and Checkmate-205 for Opdivo, which also evaluated these agents in similarly heavily pretreated cHL patients, reported ORRs of 71.4% and 69%, respectively. While the initial ORRs for AZD-3470 at the 600mg dose (63%) are currently slightly lower than these benchmarks, it’s crucial to remember that the PRIMAVERA study is in its early Phase I stage. The focus at this point is primarily on establishing safety and identifying an optimal dose range.
Furthermore, the fact that AZD-3470, as a monotherapy, is demonstrating response rates that are approaching those of established immunotherapy agents in a highly refractory patient population is a testament to its potential. The primary challenge for patients with R/R cHL is often resistance to all existing treatment modalities. Achieving a clinically meaningful response in such individuals, particularly with a novel mechanism of action, represents a substantial step forward. The indication has not seen a new first-in-class drug enter the market since the advent of PD-1 inhibitors in 2016, highlighting the unmet need for innovative therapies.
Future Directions: Expanding the Trial and Optimizing Dosing
The PRIMAVERA study is designed to continue its recruitment to a total of 161 patients across 29 global sites. This expansion will allow for a more comprehensive evaluation of AZD-3470’s safety and efficacy, including the collection of crucial secondary endpoints such as progression-free survival (PFS), duration of response, and overall survival (OS). These longer-term data will be critical in determining the drug’s ultimate clinical utility.
AstraZeneca is also planning further dose optimization and cohort expansion within the PRIMAVERA trial. This strategic approach aims to refine the dosing regimen to maximize both efficacy and tolerability, potentially leading to even higher response rates and improved patient outcomes. The ongoing nature of the trial underscores the commitment to thoroughly investigate AZD-3470’s potential.
The Broader Landscape: PRMT5 Inhibitors as an Emerging Class
The promising results for AZD-3470 at ASCO 2026 are not isolated. They represent a significant development within the rapidly evolving field of PRMT5 inhibitors. This class of drugs is gaining considerable attention due to the widespread relevance of MTAP deficiency and PRMT5 dysregulation beyond cHL. MTAP deficiency, the very condition that drives PRMT5 upregulation in cHL, is observed in approximately 15% of all solid tumors. Furthermore, epigenetic silencing mechanisms are implicated in a range of hematological malignancies.
This broad applicability has spurred significant investment and research from major pharmaceutical players. Companies such as Bristol Myers Squibb (BMS), Tango Therapeutics, Johnson & Johnson, and Bayer are all actively developing PRMT5 inhibitors. This competitive landscape suggests a growing recognition of the therapeutic potential of targeting this pathway.
Currently, BMS’s navlimetostat and Tango Therapeutics’ vopimetostat are considered frontrunners in the development of PRMT5 inhibitors for solid tumors. Both have received FDA Fast Track designations and have presented favorable Phase I safety data, which appears to be consistent with the initial findings for AZD-3470 in the PRIMAVERA trial.
Market Potential and Strategic Positioning
The emergence of PRMT5 inhibitors as a therapeutic class holds substantial market potential. Analyst consensus forecasts suggest that the global PRMT5 inhibitor market could reach an impressive $1.2 billion by 2031, highlighting the significant unmet need and the anticipated success of these novel agents.
AstraZeneca’s strategic advantage may lie in its current position as the first company to investigate PRMT5 inhibition specifically for hematological malignancies. While competition is intensifying, particularly in the solid tumor space, establishing a strong foothold in R/R cHL could provide a powerful differentiation strategy. The company has also initiated a Phase I/II trial, PRIMROSE (NCT06130553), to explore AZD-3470’s potential in solid tumors, indicating a broader ambition for this drug candidate.
However, the market for PRMT5 inhibitors remains speculative until robust registrational trial data becomes available. The success of AZD-3470, and indeed other PRMT5 inhibitors, will ultimately depend on their ability to demonstrate clear clinical benefit, superior safety profiles, and ultimately, improve patient outcomes in their respective indications. The race to develop and launch differentiated PRMT5 inhibitors across the oncology sector promises to be an exciting and closely watched development in the coming years.
The initial data from the PRIMAVERA study represent a crucial step in validating AZD-3470’s potential. As AstraZeneca continues to advance this investigational therapy, the oncology community will be keenly observing its progress, hopeful that it will bring a much-needed new treatment option to patients battling refractory classical Hodgkin Lymphoma and potentially other cancers driven by PRMT5 dysregulation.
About the Author
